0001209191-20-055562.txt : 20201022
0001209191-20-055562.hdr.sgml : 20201022
20201022161209
ACCESSION NUMBER: 0001209191-20-055562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201020
FILED AS OF DATE: 20201022
DATE AS OF CHANGE: 20201022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 201255042
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-20
1
0001799448
Aligos Therapeutics, Inc.
ALGS
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Common Stock
2020-10-20
4
C
0
1335048
A
1335048
D
Common Stock
2020-10-20
4
C
0
571143
A
1906191
D
Series B-1 convertible Preferred Stock
2020-10-20
4
C
0
1335048
0.00
D
Common Stock
1335048
0
D
Series B-2 convertible Preferred Stock
2020-10-20
4
C
0
571143
0.00
D
Common Stock
571143
0
D
The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of
Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no
expiration date.
Wellington Biomedical Innovation Master Investors
(Cayman) I L.P., By: Wellington Alternative
Investments, as General Partner, By: /s/ Peter N.
McIsaac, Title: Managing Director & Counsel
2020-10-22